Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/gwj7qh82

"ADVANCES IN ANXIETY RESEARCH: ASSESSING THE ANXIOLYTIC EFFECTS OF NOVEL COMPOUNDS IN EXPERIMENTAL GAD MODELS"

Naresh Jogadiya[1], Dr. Pragnesh Patani[2*], Mr. Rahul Kannar[3], Dr. Nishkruti R. Mehta[4]

[1]Student, Khyati College of Pharmacy, Palodiya, Ahmedabad
[2*]Principal, Khyati College of Pharmacy, Palodiya, Ahmedabad
[3]Assistant Professor, Department of Pharmacology, Khyati College of Pharmacy, Palodiya, Ahmedabad
[4]Professor and Head, Department of Pharmacology, Khyati College of Pharmacy, Palodiya, Ahmedabad

[*]**Corresponding Author:** Dr. Pragnesh Patani
[*]Principal, Khyati College of Pharmacy, Palodiya, Ahmedabad, Email: pragnesh006@gmail.com

Abstract:
Background: Generalized Anxiety Disorder (GAD) is a prevalent and debilitating mental health condition characterized by excessive and persistent worry. Current pharmacological treatments often exhibit delayed onset and undesirable side effects, highlighting the need for more effective and better-tolerated anxiolytic agents.
Objective: This study aimed to evaluate the anxiolytic potential of newly developed compounds using validated experimental models of GAD in preclinical settings.
Methods: A series of novel chemical entities were synthesized and screened for anxiolytic activity using established rodent models, including the Elevated plus Maze (EPM), Open Field Test (OFT), and Light-Dark Box test. Behavioural outcomes were compared against standard anxiolytics such as diazepam. Neurochemical assays and receptor-binding studies were conducted to elucidate the mechanisms of action.
Results: Several novel compounds demonstrated significant anxiolytic-like effects in rodent models without impairing locomotor activity. Preliminary data suggest modulation of GABAergic and serotonergic pathways, with some compounds showing partial agonist activity at the GABA-A receptor and selectivity for 5-HT1A receptors.
Conclusions: The findings support the therapeutic potential of these new compounds as effective anxiolytics with favorable safety profiles. Further pharmacokinetic and clinical investigations are warranted to explore their applicability in human GAD treatment.

Keywords: Generalized Anxiety Disorder, Anxiolytics, Novel Compounds, Rodent Models, GABA-A Receptor, 5-HT1A Receptor, Behavioural Pharmacology

1. Introduction

Generalized Anxiety Disorder (GAD) is a chronic psychiatric condition characterized by excessive, uncontrollable worry and heightened tension that occurs more days than not, for a period of at least six months. It is often accompanied by symptoms such as restlessness, fatigue, impaired concentration, irritability, muscle tension, and sleep disturbances. GAD affects millions globally and

significantly impairs daily functioning, occupational productivity, and overall quality of life. Despite its prevalence and the burden it imposes on individuals and healthcare systems, therapeutic options remain suboptimal.

Current pharmacological treatments for GAD primarily include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and benzodiazepines. [(1)] While these agents offer symptom relief for some patients, they are associated with several limitations. SSRIs and SNRIs often require several weeks to exert therapeutic effects and may produce adverse effects such as gastrointestinal disturbances, sexual dysfunction, and emotional blunting. Benzodiazepines, although effective in reducing anxiety symptoms rapidly, carry a high risk of dependence, tolerance, sedation, and cognitive impairment, especially with long-term use. [(2)]These limitations create a significant need for novel anxiolytic agents that are both effective and better tolerated.

In recent years, advances in neurobiology and pharmacology have expanded our understanding of the neural mechanisms underlying anxiety. Multiple neurotransmitter systems, including gamma-amino butyric acid (GABA), serotonin (5-HT), glutamate, and neuropeptides, play a role in the modulation of anxiety-related behaviours. This growing knowledge has opened new avenues for the development of targeted therapeutic compounds aimed at modulating specific pathways involved in anxiety regulation.

Preclinical models play a critical role in the early stages of drug development, allowing researchers to investigate the behavioural and biochemical effects of potential anxiolytic agents before proceeding to clinical trials. [(3)] Rodent-based models, such as the Elevated plus Maze (EPM), Open Field Test (OFT), and Light-Dark Box test, are widely used to evaluate anxiety-like behaviours and to screen for anxiolytic activity. These models are considered valid and reliable proxies for assessing the efficacy of new compounds in alleviating anxiety symptoms.

The present study focuses on evaluating a new class of chemical compounds with potential anxiolytic properties using validated experimental models of GAD. By examining behavioural responses and conducting preliminary mechanistic investigations, this research aims to identify promising candidates that may overcome the limitations of existing treatments. [(4)] Through a combination of behavioural pharmacology and neurochemical analysis, the study seeks to contribute meaningful insights to the ongoing search for safer and more effective therapeutic options for individuals suffering from GAD.

2. Pathophysiology of Generalized Anxiety Disorder (GAD)

Generalized Anxiety Disorder (GAD) is a multifaceted psychiatric condition with complex neurobiological underpinnings. [(5)]While the clinical presentation centres around chronic and excessive worry, the underlying mechanisms involve an intricate interplay of neurotransmitter systems, hormonal regulation, immune signaling, and gut-brain communication. Understanding these pathophysiological elements is essential for the development of more targeted and effective therapeutic strategies.

Neurobiological Basis: Role of GABAergic, Serotonergic, and Glutamatergic Systems

The regulation of anxiety is critically dependent on the balance between excitatory and inhibitory signalling within the central nervous system. Three major neurotransmitter systems—GABAergic, serotonergic, and glutamatergic—play central roles in this process.

The GABAergic system, particularly through the action of GABA-A receptors, is responsible for inhibitory neurotransmission. A deficiency or dysfunction in GABA signaling has been consistently linked with increased anxiety-like behaviours. [(6)] Many established anxiolytic medications, including benzodiazepines, exert their effects by enhancing GABAergic activity, which supports the notion that GABA dysregulation is a core feature of GAD.

The serotonergic system, involving serotonin (5-HT) and its multiple receptor subtypes (notably 5-HT1A), also plays a crucial role in mood and anxiety regulation. Hypoactivity of serotonergic pathways has been associated with increased anxiety, and the clinical efficacy of selective serotonin reuptake inhibitors (SSRIs) further underscores serotonin's role in GAD pathophysiology. [(7)]

However, the delayed onset of therapeutic action and variable patient response suggest that serotonergic modulation alone may not fully address the disorder.

In contrast, the glutamatergic system, responsible for excitatory neurotransmission, has gained attention for its contribution to anxiety states. Elevated glutamate levels or increased receptor activity (especially NMDA receptors) may lead to heightened arousal and stress responsiveness. [8] Emerging therapies aimed at modulating glutamate transmission—such as NMDA receptor antagonists—have shown promise in preclinical anxiety models.

Dysregulation of the Hypothalamic–Pituitary–Adrenal (HPA) Axis

The HPA axis governs the body's stress response and is a key hormonal system implicated in anxiety disorders. In individuals with GAD, there is evidence of chronic activation or dysregulation of the HPA axis, often characterized by altered cortisol secretion patterns.

Under stress, the hypothalamus releases corticotropin-releasing hormone (CRH), stimulating the pituitary gland to secrete adrenocorticotropic hormone (ACTH), which in turn prompts cortisol release from the adrenal glands. [9] In GAD, either a heightened baseline cortisol level or an exaggerated response to stress can occur, contributing to sustained anxiety and physiological hyperarousal.

Moreover, CRH receptors in limbic structures such as the amygdala and hippocampus further mediate anxiety-related behaviours, linking neuroendocrine changes with neural circuit dysfunction.

Neuroinflammatory Markers and Oxidative Stress in Anxiety

Chronic anxiety has been associated with low-grade neuroinflammation and increased oxidative stress. Elevated levels of pro-inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP), have been observed in individuals with anxiety disorders, including GAD.

These inflammatory mediators can disrupt neurotransmitter synthesis, impair neuroplasticity, and alter neural circuit function, particularly in regions involved in emotion regulation like the prefrontal cortex and amygdala. [10]Similarly, oxidative stress—resulting from an imbalance between reactive oxygen species (ROS) and antioxidant defences—can damage cellular components and exacerbate neural dysfunction.

The presence of inflammation and oxidative stress not only reflects underlying pathophysiology but also suggests potential therapeutic targets, including anti-inflammatory agents and antioxidants.

Emerging Role of the Gut–Brain Axis and Microbiota

Recent research has brought attention to the gut–brain axis, a bidirectional communication network linking the gastrointestinal tract with the central nervous system. The gut microbiota plays a pivotal role in this axis, influencing brain function and behaviour through neural, immune, endocrine, and metabolic pathways. [11]

Alterations in gut microbiota composition—termed dysbiosis—have been linked to increased anxiety-like behaviours in both animal models and human studies. [12] Microbial metabolites such as short-chain fatty acids (SCFAs), tryptophan metabolites, and certain neuroactive compounds can affect central neurotransmission, inflammation, and stress responses.

Moreover, interventions aimed at modifying the gut microbiome, including probiotics and dietary changes, have shown potential in reducing anxiety symptoms. [13] This emerging area offers a novel perspective on GAD pathophysiology and represents a promising avenue for future therapeutic exploration.

3. Experimental Models of Anxiety

Experimental models of anxiety in rodents are essential tools in preclinical research for understanding the neurobiology of anxiety and for screening potential anxiolytic compounds. These models rely on the natural behavioural tendencies of rodents, such as their aversion to open and brightly lit spaces, preference for dark and enclosed areas, and sensitivity to novel environments. [14] One of the most

commonly used paradigms is the **Elevated plus Maze (EPM)**, which consists of a cross-shaped apparatus elevated above the floor, with two open arms and two enclosed arms. Rodents are placed in the center, and their movements are recorded. Rodents generally avoid open arms due to the risk of falling or exposure to predators. Therefore, increased exploration of the open arms following administration of an anxiolytic drug indicates a reduction in anxiety. [15] This model is particularly sensitive to benzodiazepines and other fast-acting anxiolytic agents.

Another frequently used method is the **Open Field Test (OFT)**, which measures both anxiety and general locomotor activity. The test arena is a large, enclosed, open box—usually brightly lit—and rodents are observed for their activity levels, particularly how much time they spend in the central versus peripheral zones. [16] Anxious rodents typically display thigmotaxis, staying close to the walls (periphery), while less anxious rodents venture more into the center. The OFT can also provide insights into behavioural inhibition, grooming behaviour, and rearing, which are all indicators of emotional state. Though less specific to anxiety compared to EPM, the OFT is useful when combined with other behavioural tests.

The **Light/Dark Box Test** exploits the rodent's innate aversion to light and preference for dark, enclosed spaces. The apparatus is divided into two compartments: one brightly lit and one dark. [17] Rodents are placed in the dark compartment at the beginning of the test, and their transitions between the two areas, as well as the time spent in each compartment, are measured. An increased number of transitions and time spent in the light chamber indicate reduced anxiety levels, typically in response to anxiolytic treatment. This test is particularly sensitive to benzodiazepines and is easy to conduct with minimal training.

The **Vogel Conflict Test** provides a more complex and challenging paradigm, involving a conflict between a biological drive (thirst) and an aversive stimulus (mild foot shock). In this test, water-deprived rodents are allowed to drink from a spout that delivers a small electric shock after a certain number of licks. [18] The number of licks or punished responses is recorded. A high level of anxiety suppresses the licking behaviour despite thirst, while anxiolytic drugs tend to increase the number of punished licks by reducing anxiety-related inhibition. This test is particularly sensitive to compounds that target GABAergic systems but is more technically demanding due to the use of electrical stimuli.

Finally, the **Novelty-Suppressed Feeding Test (NSFT)** is used to evaluate anxiety under conditions of conflict and novelty. Rodents are food-deprived for 24 hours and then placed in a new, brightly lit environment with food placed in the center of the arena. The latency to approach and begin eating is recorded. An anxious animal will hesitate to approach the food due to the unfamiliar surroundings. A reduced latency, often observed after chronic treatment with antidepressants or anxiolytics, reflects a decrease in anxiety-like behaviours. [19] This test is particularly useful for studying the effects of chronic stress or evaluating long-term treatment efficacy, as it is sensitive to serotonergic modulation and stress-induced behavioural changes.

Each of these models offers distinct advantages and limitations, and they are often used in combination to provide a more comprehensive evaluation of anxiety-related behaviour. The choice of test depends on the specific research question, the pharmacological agent being studied, and the behavioural profile of the animal model. Together, they form the foundation of behavioural neuroscience research on anxiety and are instrumental in advancing our understanding of emotional regulation and the development of new therapeutic interventions.

Table 1: Experimental Models of Anxiety and Their Applications

Experimental Model	Description	Behavioural Measures	Applications / Uses	Strengths	Limitations
Elevated Plus Maze (EPM)	Cross-shaped maze with two open and two closed arms elevated above the floor.	Time spent in open vs. closed arms, number of entries into each arm	Assessment of anxiety-related avoidance behaviours and exploration	Simple, widely used, validated for anxiety	Sensitive to locomotor activity, stressful setup
Open Field Test (OFT)	Open arena where rodents explore freely.	Time spent in center vs. periphery, total locomotion	Measures anxiety, general locomotor activity, exploratory behaviours	Easy to perform, assesses anxiety and activity	Can be influenced by novelty and habituation
Light/Dark Box Test	Chamber divided into a brightly lit and a dark compartment.	Time spent in light vs. dark area, number of transitions	Measures anxiety based on aversion to bright areas	Reflects natural aversion to light, rapid testing	Variability in lighting conditions can affect results
Vogel Conflict Test	Water-deprived rodents receive mild shocks when drinking from a spout.	Number of punished licks (suppression of drinking due to punishment)	Assesses conflict between drive and punishment (anxiety)	Sensitive to anxiolytic drugs, measures conflict behaviours	Requires deprivation, more complex setup
Novelty-Suppressed Feeding Test	Food-deprived rodents introduced to novel environment with food placed centrally.	Latency to begin feeding	Assesses anxiety-related inhibition of motivated behaviours	Sensitive to chronic treatment effects	Influenced by hunger level and motivational factors

4. Conventional Pharmacological Interventions

Conventional pharmacological interventions for anxiety disorders, particularly generalized anxiety disorder (GAD), have focused on targeting neurotransmitter systems involved in mood regulation, especially the GABAergic and serotonergic pathways. One of the most commonly prescribed classes for acute anxiety relief is benzodiazepines, which act as positive allosteric modulators of the GABA-A receptor. [20]They provide a rapid and effective anxiolytic effect by enhancing inhibitory neurotransmission, resulting in sedation, muscle relaxation, and reduced psychological distress. [21] However, despite their fast onset of action, benzodiazepines are associated with significant drawbacks, including the development of tolerance, physical dependence, and the risk of withdrawal symptoms upon discontinuation. Long-term use can also impair cognitive and psychomotor functioning, making them less suitable for chronic management.

In contrast, antidepressants, particularly Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), are considered first-line treatments for long-term management of anxiety disorders. [22] These medications increase the availability of serotonin (and norepinephrine in the case of SNRIs) in the synaptic cleft, which gradually improves mood and reduces anxiety symptoms. Although they have demonstrated strong efficacy in numerous clinical

trials, a major limitation is their delayed onset of action, often requiring several weeks before therapeutic benefits are observed. [23] Moreover, during the initial treatment period, patients may experience heightened anxiety, gastrointestinal disturbances, or insomnia, which can impact adherence. Tricyclic antidepressants (TCAs), an older class of antidepressants, are also effective but are generally reserved for treatment-resistant cases due to their anticholinergic side effects and cardiovascular risks.

Buspirone, a non-benzodiazepine anxiolytic, offers a different pharmacological approach. It functions as a partial agonist at the 5-HT1A receptor, modulating serotonergic activity without causing sedation, dependence, or cognitive impairment. Its anxiolytic effects are more subtle compared to benzodiazepines, and it typically takes two to four weeks to produce noticeable improvements. Buspirone is best suited for patients with mild to moderate anxiety and is particularly useful when long-term treatment is needed without the risk of dependence. [24] However, its efficacy is somewhat limited in individuals with severe anxiety or those previously treated with benzodiazepines.

For individuals with treatment-resistant GAD, who do not respond adequately to first-line medications, alternative strategies may include the use of cognitive enhancers and atypical antipsychotics. Certain cognitive enhancers, such as modafinil or low-dose D-cycloserine, are being explored for their potential to augment cognitive-behavioural therapy (CBT) and enhance neuroplasticity. [25] Meanwhile, atypical antipsychotics like quetiapine and aripiprazole have shown some promise in off-label use for anxiety due to their serotonergic and dopaminergic activity. These agents may be effective in reducing anxiety symptoms, particularly in cases with comorbid mood disorders, but their use is limited by concerns over metabolic side effects, sedation, and long-term safety.

Overall, pharmacological treatment of anxiety requires a careful balance between efficacy, onset of action, side effect profile, and risk of dependence. [26]Clinicians must tailor interventions to individual patient needs, often combining medication with psychotherapy to achieve the best outcomes.

Table 2: Conventional vs. Novel Anxiolytics

Aspect	Conventional Anxiolytics	Novel Anxiolytics
Examples	Benzodiazepines, SSRIs, SNRIs, TCAs, Buspirone	Phytochemicals (CBD, curcumin), neurosteroids, glutamate modulators, endocannabinoid modulators, epigenetic agents
Mechanism of Action	Primarily GABAergic modulation (benzodiazepines), serotonergic and noradrenergic modulation (SSRIs, SNRIs, TCAs), partial 5-HT1A agonise (buspirone)	Diverse: modulation of GABAergic and glutamatergic systems, neuropeptides, endocannabinoid signaling, neuroplasticity, epigenetic regulation
Onset of Action	Benzodiazepines: rapid; Antidepressants: delayed (weeks)	Some novel agents show rapid anxiolytic effects (e.g., NMDA antagonists), others may vary
Efficacy	Effective but limited by tolerance and dependence (benzodiazepines); variable efficacy with delayed response (antidepressants)	Promising efficacy in preclinical studies; may have better side effect profiles and novel mechanisms
Side Effects	Sedation, cognitive impairment, dependence, withdrawal symptoms, sexual dysfunction (antidepressants)	Generally fewer sedative effects; potential for fewer cognitive side effects; safety profiles still under investigation
Tolerance & Dependence	High risk, especially with benzodiazepines	Lower risk anticipated, but long-term studies are needed
Treatment Resistance	Some patients do not respond adequately	Novel compounds and combined therapies aim to address resistance
Clinical Use	Widely used, FDA-approved	Mostly in experimental or early clinical trial phases
Additional Benefits	Some antidepressants also improve comorbid depression	Potential neuroprotective and cognitive-enhancing properties

5. Novel Compounds with Anxiolytic Potential

The search for novel anxiolytic compounds has expanded significantly beyond conventional pharmacotherapies, with current research focusing on diverse molecular targets and pathways implicated in anxiety regulation. [27] These emerging approaches include phytochemicals, neuropeptides, endocannabinoid system modulators, glutamatergic agents, neurosteroids, epigenetic modifiers, and microbiota-based therapies, each offering unique mechanisms of action and potential therapeutic advantages.

Phytochemicals, naturally occurring compounds in plants, have shown promising anxiolytic properties in preclinical and clinical studies. Among these, flavonoids such as *quercetin* exhibit antioxidant and anti-inflammatory effects, modulating GABAergic and serotonergic pathways associated with anxiety. [28] Curcumin, a polyphenol derived from turmeric, has been found to influence neurotransmitter levels and reduce inflammation and oxidative stress in the brain, which are often linked to anxiety disorders. [29] Another widely studied compound is cannabidiol (CBD), a non-psychoactive component of *Cannabis sativa*, which interacts with the endocannabinoid system and serotonin receptors to reduce anxiety-like behaviour without the addictive properties of THC. These plant-derived compounds present fewer side effects and may serve as adjunct or alternative treatments for anxiety.

Neuropeptides are short chains of amino acids that act as signaling molecules in the brain and are deeply involved in regulating mood and emotional responses. Oxytocin, often referred to as the "social bonding hormone," has garnered attention for its anxiolytic effects, particularly in enhancing trust, reducing fear, and promoting social interaction. Intranasal administration of oxytocin has been explored in anxiety disorders with mixed but encouraging results. Conversely, vasopressin, another neuropeptide, has been implicated in stress and anxiety enhancement. [30] Therefore, vasopressin receptor antagonists are being studied as potential anxiolytics, aiming to dampen the stress response and reduce anxiety symptoms, especially in social and generalized anxiety disorders.

The endocannabinoid system plays a vital role in emotional regulation and stress adaptation. Modulation of this system is a promising approach for developing new anxiolytic agents. CB1 and CB2 receptor agonists can influence neurotransmitter release and reduce hyperactivity in anxiety circuits. [31] However, concerns about psychoactive side effects and dependence limit their direct clinical use. As a result, attention has shifted to fatty acid amide hydrolase (FAAH) inhibitors, which prevent the breakdown of anandamide, an endogenous cannabinoid. By increasing anandamide levels, FAAH inhibitors can enhance endocannabinoid signaling and reduce anxiety-like behaviour without directly activating cannabinoid receptors, thereby minimizing unwanted side effects.

Glutamatergic modulation represents another innovative target for anxiety treatment. The NMDA receptor, a subtype of glutamate receptor, has been linked to synaptic plasticity and emotional learning. [32] NMDA antagonists, such as ketamine, have shown rapid and robust anxiolytic and antidepressant effects in resistant cases, though concerns about dissociative effects and abuse potential persist. Additionally, metabotropic glutamate receptors (mGluRs), particularly mGluR2/3 and mGluR5 subtypes, are being investigated for their role in fine-tuning glutamate transmission. [33] Modulating these receptors may offer a subtler and safer approach to reducing excitatory signaling associated with anxiety disorders.

Neurosteroids are steroid compounds synthesized in the brain that modulate GABA-A receptor activity, similar to benzodiazepines but with potentially fewer side effects. Allopregnanolone, a potent neurosteroid, enhances GABAergic inhibition and has shown significant anxiolytic and antidepressant properties. Synthetic analogs of allopregnanolone are being developed for clinical use, including treatments for postpartum depression and anxiety-related conditions. [34] These compounds provide rapid symptom relief and may represent a safer alternative to traditional sedatives.

Epigenetic modifiers are another frontier in anxiety treatment, focusing on the long-term regulation of gene expression without altering DNA sequences. Histone deacetylase (HDAC) inhibitors are among the most studied agents in this category. By promoting histone acetylation, these compounds increase the expression of genes involved in neuroplasticity and stress resilience. [35] Preclinical studies suggest that HDAC inhibitors may reverse stress-induced epigenetic changes and exert lasting

anxiolytic effects. While still in early stages of development, these agents could pave the way for personalized and long-lasting treatments.

Lastly, the gut-brain axis has become a central area of interest, with growing evidence linking gut microbiota composition to mental health. Microbiota-based therapies, including psychobiotics, prebiotics, and probiotics, aim to restore healthy gut flora to influence brain function and behaviour.[36]Certain probiotic strains, such as *Lactobacillus* and *Bifidobacterium*, have been shown to reduce anxiety-like behaviour in both animal models and human trials, likely through mechanisms involving vagus nerve signaling, immune modulation, and the production of neuroactive compounds like GABA.[37]These therapies offer a non-invasive, holistic approach to anxiety management and may be particularly useful as adjuncts to conventional treatment.

6. Mechanisms of Action of Novel Compounds

The mechanisms of action of novel anxiolytic compounds involve targeting a broad range of neurobiological systems beyond those addressed by conventional treatments. These new approaches aim to offer improved efficacy, faster onset of action, and fewer side effects by addressing the underlying pathophysiology of anxiety disorders. [38] The most prominent mechanisms include modulation of GABAergic and glutamatergic neurotransmission, regulation of serotonergic and dopaminergic pathways, reduction of oxidative stress and neuroinflammation, enhancement of neuroplasticity through the BDNF pathway, and epigenetic regulation of stress-responsive genes.

One key mechanism is the modulation of GABAergic and glutamatergic neurotransmission, which are the primary inhibitory and excitatory systems in the brain, respectively. Novel compounds such as neurosteroids (e.g., allopregnanolone analogs) enhance GABA-A receptor function, promoting inhibitory signaling and reducing neural excitability associated with anxiety. Unlike benzodiazepines, these compounds may avoid issues like tolerance and dependence. [39] On the excitatory side, targeting the glutamatergic system, particularly the NMDA receptors and metabotropic glutamate receptors (mGluRs), helps to regulate excessive excitatory activity that contributes to anxiety symptoms. NMDA antagonists can produce rapid anxiolytic effects by dampening overactive circuits, while mGluR modulators offer more precise and potentially safer control over glutamate signaling.

Another important mechanism involves the regulation of serotonergic and dopaminergic pathways, both of which are closely tied to mood and anxiety. [40] Novel agents such as buspirone and certain phytochemicals (like cannabidiol) influence serotonin receptors, particularly 5-HT1A, which are critical in mediating anxiety-related behaviour. Modulation of this receptor can improve emotional regulation and reduce anxiety without causing sedation or dependence. Dopaminergic signaling, particularly in the mesolimbic pathway, is also implicated in the motivational and reward components of anxiety and stress. Agents that fine-tune dopamine release or receptor sensitivity may help alleviate anhedonia and hyper vigilance often observed in anxiety disorders.

Reduction of oxidative stress and neuroinflammation represents another significant area of focus. Chronic stress and anxiety have been linked to increased levels of reactive oxygen species and pro-inflammatory cytokines, which can impair neuronal function and connectivity. Many phytochemicals, such as curcumin and quercetin, exhibit strong antioxidant and anti-inflammatory properties. [41] These compounds help protect neurons from damage, restore homeostasis in the central nervous system, and reduce anxiety-like behaviour by improving the brain's internal environment. Targeting inflammation is particularly promising in anxiety conditions associated with systemic or neuroinflammatory states.

Enhancement of neuroplasticity, especially through the brain-derived neurotropic factor (BDNF) pathway, is central to several novel therapeutic strategies. BDNF supports the survival, growth, and differentiation of neurons and plays a key role in synaptic plasticity and cognitive function. Decreased BDNF levels have been observed in individuals with anxiety disorders. [42] Novel compounds that up regulate BDNF expression—either directly or via signaling pathways such as the ERK/MAPK and PI3K/Akt pathways—may reverse stress-induced neural deficits and promote emotional resilience. Enhancing neuroplasticity not only improves current symptoms but may also reduce the long-term vulnerability to anxiety.

Lastly, epigenetic modulation of stress-responsive genes offers a promising and long-lasting approach to treating anxiety. Epigenetic changes, such as histone acetylation and DNA methylation, can influence gene expression without altering the genetic code itself. [43] Agents like histone deacetylase (HDAC) inhibitors work by increasing acetylation, thereby promoting the expression of genes involved in stress resilience and neural plasticity, including BDNF. By targeting these molecular switches, it may be possible to "reprogram" stress-related gene expression patterns, providing sustained relief from anxiety symptoms and potentially preventing relapse. This approach is particularly valuable in addressing the long-term effects of early-life stress or trauma.

Table 3: Mechanisms of Action of Novel Compounds in Anxiety

Mechanism	Description	Examples of Novel Compounds/Targets	Therapeutic Implications
Modulation of GABAergic Neurotransmission	Enhances inhibitory signaling to reduce neuronal excitability and anxiety	Neurosteroids (allopregnanolone analogs), phytochemicals	Rapid anxiolytic effects with potentially lower tolerance risk
Modulation of Glutamatergic Neurotransmission	Regulates excitatory signaling involved in stress and anxiety circuits	NMDA receptor antagonists, mGluR modulators	Rapid relief of anxiety symptoms; improved cognitive outcomes
Regulation of Serotonergic Signaling	Alters serotonin receptor activity influencing mood and anxiety	Partial 5-HT1A agonists (buspirone), cannabidiol (CBD)	Improved emotional regulation with reduced side effects
Regulation of Dopaminergic Signaling	Modulates dopamine pathways impacting motivation and reward processing	Dopamine receptor modulators, neuropeptides	Addresses anhedonia and stress-related motivational deficits
Reduction of Oxidative Stress and Neuroinflammation	Decreases harmful reactive oxygen species and inflammation linked to anxiety	Phytochemicals (curcumin, quercetin), endocannabinoid modulators	Protects neurons and restores neural homeostasis
Enhancement of Neuroplasticity (BDNF Pathway)	Promotes synaptic growth, connectivity, and adaptive brain responses	Agents increasing BDNF expression, HDAC inhibitors	Supports recovery from stress-induced neural damage and improves resilience
Epigenetic Modulation	Alters gene expression patterns related to stress response without changing DNA sequence	Histone deacetylase (HDAC) inhibitors	Potential for long-term therapeutic effects by "reprogramming" gene expression
Modulation of Endocannabinoid System	Influences CB1/CB2 receptors and enzymes regulating endocannabinoid levels	FAAH inhibitors, CB1/CB2 agonists	Balances mood and anxiety with neuroprotective properties
Microbiota-based Therapies	Targets gut-brain axis through probiotics, prebiotics, and psychobiotics	Specific bacterial strains or dietary interventions	Potential to modulate anxiety through immune and neurochemical pathways

7. Comparative Analysis

A comparative analysis of novel anxiolytic compounds versus conventional anxiolytics reveals important insights into their relative efficacy, translational potential, and safety. While traditional agents like benzodiazepines and certain antidepressants remain the clinical standard for anxiety treatment, newer compounds are showing significant promise in preclinical models, with the potential to overcome many limitations of existing therapies. [44] However, challenges remain in translating these findings from animal studies to human applications, and a careful evaluation of dose–response relationships and safety profiles is essential to guide clinical development.

In terms of efficacy, conventional anxiolytics such as benzodiazepines demonstrate rapid and robust effects in both preclinical and clinical settings. These agents reliably reduce anxiety-like behaviors in established animal models such as the elevated plus maze, open field test, and light/dark box test. [45]

However, their therapeutic benefits are often accompanied by sedation, cognitive impairment, and the risk of tolerance and dependence with prolonged use. In contrast, novel compounds—including phytochemicals like cannabidiol (CBD), neurosteroids such as allopregnanolone analogs, and glutamatergic modulators like NMDA receptor antagonists—have shown anxiolytic effects in the same behavioural models without inducing sedation or addiction-like behaviour. For instance, CBD reduces anxiety in rodents via 5-HT1A and endocannabinoid pathways, while NMDA antagonists offer rapid relief in stress-induced models. These findings suggest that novel agents may provide equal or superior efficacy with fewer adverse effects, although most of this evidence remains confined to animal studies.

The translational potential of these novel compounds—the ability to convert promising results in rodent models into effective treatments for humans—presents a more complex challenge. Animal models of anxiety, while useful, cannot fully replicate the cognitive and emotional components of human anxiety disorders. Moreover, species differences in receptor distribution, metabolism, and neurocircuitry often result in discrepancies between preclinical and clinical outcomes. [46] For example, certain compounds that perform well in reducing anxiety-like behaviour in rodents may fail to show the same effect in human trials due to differences in pharmacokinetics or behavioural endpoints. Additionally, the placebo response in clinical anxiety studies is often high, which can mask the true efficacy of experimental drugs. These limitations emphasize the need for improved translational tools, such as biomarkers and imaging techniques, to bridge the gap between animal research and human application.

Understanding dose–response relationships and safety profiles is another critical step in drug development. Conventional anxiolytics have well-established dosing guidelines and known side effect profiles. [47] For instance, benzodiazepines have a narrow therapeutic window, where increasing doses may rapidly lead to sedation, motor impairment, or dependence. In contrast, many novel compounds exhibit wider therapeutic windows and fewer side effects at therapeutic doses. Neurosteroids and HDAC inhibitors, for example, have demonstrated anxiolytic effects at relatively low doses without overt behavioural suppression. However, some novel agents, such as NMDA antagonists, can have non-linear dose–response curves, where higher doses may lead to dissociative or psychotomimetic effects, highlighting the importance of careful dose titration. Moreover, long-term safety data for most novel compounds is lacking, and potential off-target effects or toxicity must be thoroughly investigated through chronic exposure studies before clinical use can be considered safe.

8. Challenges in Anxiety Research

Anxiety research faces a number of critical challenges that hinder the development of effective and reliable treatments, despite significant advances in neuroscience and pharmacology. Among the most pressing issues are the reproducibility of results, the translational gap between animal models and human anxiety, ethical concerns in experimental research, the lack of reliable biomarkers for predicting treatment response, and the impact of inter-individual variability arising from both genetic and environmental influences.[48]

One of the most significant barriers in anxiety research is the reproducibility and translational gap between preclinical animal studies and clinical outcomes in patients with Generalized Anxiety Disorder (GAD). Animal models, such as the elevated plus maze or open field test, are invaluable for studying anxiety-like behaviours and testing new compounds. However, these models primarily measure avoidance behaviour and stress reactivity, which do not fully capture the cognitive, emotional, and social dimensions of anxiety in humans. As a result, many compounds that show robust anxiolytic effects in rodents fail to demonstrate similar efficacy in clinical trials.[49] Furthermore, differences in neurobiology, metabolism, and receptor expression between species complicate the interpretation and application of animal data to human populations. This translational disconnect is a major reason why many experimental treatments ultimately fail in late-stage clinical development.

Ethical considerations in anxiety research, especially when using animal models, also pose significant challenges. While animal testing remains a cornerstone of preclinical research, it raises concerns regarding the welfare and humane treatment of laboratory animals. Procedures such as restraint stress,

foot shocks, or social isolation, which are used to induce anxiety-like states in rodents, may cause undue suffering. [50] Ethical guidelines and regulations aim to minimize harm through the principles of the 3Rs—Replacement, Reduction, and Refinement—but balancing scientific rigor with ethical responsibility remains complex. In human studies, ethical challenges revolve around informed consent, especially when testing experimental treatments with unknown risks, and ensuring that participants with anxiety disorders are not placed in distressing situations that could exacerbate their symptoms.

Another major limitation in anxiety research is the absence of validated biomarkers that can reliably predict who will respond to a given anxiolytic treatment. Currently, treatment decisions are largely based on trial and error, with clinicians selecting medications based on symptom presentation rather than biological indicators. The identification of biomarkers—whether genetic, neuroimaging-based, hormonal, or molecular—could revolutionize anxiety treatment by allowing for personalized interventions tailored to an individual's specific neurobiology. [51] However, despite ongoing research, no such biomarkers have been consistently validated or widely implemented in clinical practice. This lack of objective diagnostic and prognostic tools contributes to inconsistent treatment outcomes and prolonged suffering for patients.

Lastly, inter-individual variability, driven by both genetic and environmental factors, significantly affects anxiety development, severity, and treatment response. Genetic polymorphisms in neurotransmitter systems, such as the serotonin transporter gene (5-HTTLPR), can influence an individual's susceptibility to anxiety and their response to medications. At the same time, environmental influences such as early-life stress, trauma, and socioeconomic conditions play a crucial role in shaping an individual's psychological resilience or vulnerability. [52] These variables not only affect the risk of developing anxiety disorders but also complicate the generalization of research findings across diverse populations. Understanding how genes and environment interact to influence anxiety is critical for developing more effective and equitable treatments.

9. Future Directions

The future of anxiety disorder research and treatment, particularly for Generalized Anxiety Disorder (GAD), is moving toward a more personalized, technology-driven, and integrative approach. Key advancements are expected in the areas of computational drug discovery, precision medicine and pharmacogenomics, combined therapeutic strategies, and rigorous clinical trials of emerging compounds. These directions aim to overcome current limitations in treatment efficacy, side-effect profiles, and individual variability, ultimately leading to more effective and targeted interventions.

One of the most transformative developments in drug discovery is the integration of computational methods and artificial intelligence (AI) in identifying new anxiolytic agents. Traditional drug development is time-consuming and costly, often taking over a decade from discovery to market. Computational drug design uses algorithms, structural modelling, and large-scale screening of chemical libraries to identify potential compounds that can interact with specific targets related to anxiety, such as GABA-A receptors, serotonin receptors, or neuroinflammatory pathways. AI-driven approaches, including machine learning models, can predict drug-receptor binding, optimize pharmacokinetic properties, and even anticipate side effects before clinical testing. This significantly accelerates the drug discovery process and allows for the identification of entirely new classes of compounds with novel mechanisms of action. These technologies also allow researchers to repurpose existing drugs for anxiety treatment based on predicted efficacy, saving both time and resources.

The rise of precision medicine and pharmacogenomics marks another crucial step forward in the treatment of GAD. Current pharmacological treatments often follow a "one-size-fits-all" model, which does not account for individual differences in drug metabolism, genetic profile, or neurochemical makeup. Pharmacogenomics examines how genetic variations affect an individual's response to medications. For instance, polymorphisms in genes encoding enzymes like CYP2D6 or CYP2C19 can influence how quickly a person metabolizes certain antidepressants or anxiolytics, affecting both efficacy and risk of side effects. Precision medicine aims to tailor treatments based on these genetic and biological factors, improving outcomes and reducing the trial-and-error process of

medication selection. In the future, genetic testing could become a routine part of anxiety treatment, guiding clinicians in choosing the most effective and safest medication for each patient.

Another promising direction involves the integration of pharmacological and behavioral therapies, recognizing that anxiety is a complex condition influenced by both biological and psychological factors. Combining medication with evidence-based psychotherapies, such as Cognitive Behavioural Therapy (CBT), can produce synergistic effects, enhancing treatment efficacy. Novel compounds that improve cognitive flexibility or emotional processing—such as glutamatergic modulators or cognitive enhancers—may also enhance the effectiveness of psychotherapy when administered in conjunction. Moreover, the use of certain agents, like D-cycloserine, has been explored as a means of enhancing fear extinction during exposure-based therapies. These combined approaches can lead to more durable and meaningful improvements in anxiety symptoms compared to either strategy alone.

Finally, the advancement of anxiety treatment depends heavily on well-designed clinical trials to validate the safety and efficacy of promising novel compounds. While many substances—such as cannabinoids, neurosteroids, and glutamate modulators—have shown anxiolytic effects in preclinical models, their success in human populations depends on careful clinical testing. Phase I and II trials assess safety, dosing, and preliminary efficacy, while Phase III trials confirm therapeutic benefit in larger, diverse populations. Importantly, modern trials are increasingly incorporating biomarkers, neuroimaging, and patient-reported outcomes to gain a deeper understanding of how these treatments work and for whom they are most effective. Continued investment in such trials, along with regulatory support, is essential for bringing new treatments to clinical practice.

10. Conclusion

In recent years, significant progress has been made in the development of novel anxiolytic treatments, expanding far beyond traditional therapies like benzodiazepines and antidepressants. Researchers have identified a wide range of new pharmacological targets, including neurosteroids, glutamatergic modulators, endocannabinoid system regulators, and natural phytochemicals, each with unique mechanisms of action that differ from conventional anxiolytics. These compounds have demonstrated promising anxiolytic effects in preclinical models by modulating neural circuits involved in stress and emotion regulation, improving neuroplasticity, and reducing neuroinflammation. Additionally, emerging approaches like epigenetic modulation and microbiota-based interventions have opened new avenues for understanding and treating anxiety disorders on a biological level.

Despite these advances, there remains a critical need for safer, more effective, and faster-acting treatments for anxiety, particularly for conditions like Generalized Anxiety Disorder (GAD), which are often chronic and resistant to standard medications. Many conventional drugs, while effective in the short term, carry significant drawbacks such as sedation, cognitive impairment, dependence, and delayed onset of action. Novel agents are being designed to minimize these limitations by targeting specific neurotransmitter systems with greater precision or by enhancing the brain's natural mechanisms of emotional regulation. Fast-acting treatments, such as certain NMDA receptor antagonists and neurosteroid analogs, hold particular promise in providing rapid relief without the addictive potential of older drugs.

A key challenge moving forward is the translation of preclinical findings into clinical applications. While animal models provide valuable insights into the neurobiological basis of anxiety and allow for early testing of drug efficacy, they cannot fully replicate the complexity of human anxiety disorders. Differences in brain structure, emotional processing, and genetic variability between species often result in discrepancies between preclinical success and clinical outcomes. Bridging this gap requires not only improved animal models but also the integration of human-based tools such as neuroimaging, genetic screening, and biomarker analysis in clinical trials. It also involves refining clinical trial design to better assess real-world effectiveness, patient-specific responses, and long-term safety.

References

1. Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015). Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics. *Annual Review of Medicine*, 66, 509-523. https://doi.org/10.1146/annurev-med-053013-062946
2. Akhondzadeh, S., Kashani, L., Mobaseri, M., et al. (2001). Crocus sativus L. (saffron) in the treatment of mild to moderate depression: A double-blind, randomized and placebo-controlled trial. *Phytomedicine*, 8(5), 263-267. https://doi.org/10.1078/094471101750257139
3. Atmaca, M. (2010). Neurobiology of anxiety disorders. *Psychiatry and Clinical Neurosciences*, 64(6), 461-470. https://doi.org/10.1111/j.1440-1819.2010.02109.x
4. Bandelow, B., Michaelis, S., & Wedekind, D. (2017). Treatment of anxiety disorders. *Dialogues in Clinical Neuroscience*, 19(2), 93-107. https://doi.org/10.31887/DCNS.2017.19.2/bbandelow
5. Basu, A., & Dasgupta, P. S. (2020). Neurobiology of anxiety disorders: Role of neurotransmitters and novel targets. *Current Neuropharmacology*, 18(10), 1053-1066. https://doi.org/10.2174/1570159X18666200515122639
6. Becker, R., Schmitt, S., & Markou, A. (2017). Translational animal models of anxiety disorders: A focus on generalized anxiety disorder. *Current Topics in Behavioural Neurosciences*, 30, 75-93. https://doi.org/10.1007/7854_2016_43
7. Biedermann, S., Zeitz, J., Mwinyi, J., et al. (2013). Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. *PLoS One*, 8(3), e59260. https://doi.org/10.1371/journal.pone.0059260
8. Bourin, M., & Hascoët, M. (2003). The mouse light/dark box test. *European Journal of Pharmacology*, 463(1-3), 55-65. https://doi.org/10.1016/S0014-2999(03)01274-3
9. Brühl, A. B., Delsignore, A., Komossa, K., & Weidt, S. (2014). Neuroimaging in social anxiety disorder – A meta-analytic review resulting in a new neurofunctional model. *Neuroscience & Biobehavioral Reviews*, 47, 260-280. https://doi.org/10.1016/j.neubiorev.2014.08.003
10. Canters, N. S., & Goto, M. (1999). Multidimensional aspects of fear memory: Neuroanatomical and neurochemistry. *Neuroscience and Biobehavioral Reviews*, 23(8), 1037-1048. https://doi.org/10.1016/S0149-7634(99)00029-1
11. Caspi, A., Sugden, K., Moffitt, T. E., et al. (2003). Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. *Science*, 301(5631), 386-389. https://doi.org/10.1126/science.1083968
12. Chen, A. C., & Etkin, A. (2013). Hippocampal network connectivity and activation differentiates post-traumatic stress disorder from generalized anxiety disorder. *Neuropsychopharmacology*, 38(10), 1889-1898. https://doi.org/10.1038/npp.2013.107
13. Choi, D. Y., & Kim, H. (2017). Phytochemicals in anxiety treatment: A review of evidence from preclinical and clinical studies. *Frontiers in Pharmacology*, 8, 20. https://doi.org/10.3389/fphar.2017.00020
14. Cryan, J. F., & Sweeney, F. F. (2011). The age of anxiety: Role of the gut microbiota in anxiety and depression. *Trends in Neurosciences*, 34(8), 427-434. https://doi.org/10.1016/j.tins.2011.05.003
15. Cunha, J. M., & Bortolatto, C. F. (2020). Novel therapeutic targets for anxiety disorders: Insights from rodent models. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 102, 109946. https://doi.org/10.1016/j.pnpbp.2020.109946
16. De Carvalho, R. F., de Almeida, J. R., & Silva, E. R. (2018). Effects of neurosteroids in anxiety: Focus on allopregnanolone analogs. *Frontiers in Pharmacology*, 9, 675. https://doi.org/10.3389/fphar.2018.00675
17. Di Mauro, M., & Renaldo, L. (2019). Epigenetic modulators as therapeutic targets in anxiety disorders. *Neuroscience Letters*, 711, 134471. https://doi.org/10.1016/j.neulet.2019.134471
18. Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016). Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. *Nature Medicine*, 22(3), 238-249. https://doi.org/10.1038/nm.4050

19. Dwyer, J. B., McQuown, S. C., & Leslie, F. M. (2009). The dynamic effects of nicotine on the developing brain. *Pharmacology & Therapeutics*, 122(2), 125-139. https://doi.org/10.1016/j.pharmthera.2009.02.003
20. Fogaça, M. V., & Duman, R. S. (2019). Cortical gabaergic dysfunction in stress and depression: New insights for novel therapeutic approaches. *Neuroscience Letters*, 733, 135069. https://doi.org/10.1016/j.neulet.2019.135069
21. Francesconi, W., & Berton, O. (2021). Neuropeptides in anxiety and depression: Therapeutic perspectives. *Frontiers in Molecular Neuroscience*, 14, 621595. https://doi.org/10.3389/fnmol.2021.621595
22. Gielen, M., & Houwing, D. J. (2018). Microbiota-gut-brain axis in anxiety: From mechanism to intervention. *Journal of Neuroendocrinology*, 30(9), e12667. https://doi.org/10.1111/jne.12667
23. Griebel, G., & Holmes, A. (2013). 50 years of hurdles and hope in anxiolytic drug discovery. *Nature Reviews Drug Discovery*, 12(9), 667-687. https://doi.org/10.1038/nrd4095
24. Grillon, C. (2008). Models and mechanisms of anxiety: Evidence from startle studies. *Psychopharmacology*, 199(3), 421-437. https://doi.org/10.1007/s00213-008-1236-6
25. Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., & Zuardi, A. W. (1990). Antianxiety effect of cannabidiol in the elevated plus-maze. *Psychopharmacology*, 100(4), 558-559. https://doi.org/10.1007/BF02244002
26. Hammoud, S., Ibrahim, R., & Noureldin, A. (2020). Endocannabinoid modulation and anxiety disorders: A review. *Neuroscience Letters*, 726, 133814. https://doi.org/10.1016/j.neulet.2020.133814
27. Hasler, G., & Northoff, G. (2011). Discovering imaging endophenotypes for major depression. *Molecular Psychiatry*, 16(6), 604-619. https://doi.org/10.1038/mp.2010.125
28. Heim, C., & Nemeroff, C. B. (2009). Neurobiology of early life stress: Clinical studies. *Seminars in Clinical Neuropsychiatry*, 4(1), 50-56. https://doi.org/10.1055/s-0029-1216283
29. Hiraoka, Y., & Kaneko, N. (2018). Novel approaches to anxiety treatment: Role of neuropeptides and neurosteroids. *Current Neuropharmacology*, 16(8), 1232-1242. https://doi.org/10.2174/1570159X16666180705153935
30. Holmes, A., & Rodgers, R. J. (1998). Responses of mice to anxiolytic drugs in the elevated plus-maze test: Genetic and pharmacological influences. *Neuroscience & Biobehavioral Reviews*, 22(5), 723-738. https://doi.org/10.1016/S0149-7634(98)00065-3
31. Insel, T. R., & Landis, S. C. (2013). Twenty-five years of progress: The NIH BRAIN Initiative. *Neuron*, 80(3), 504-507. https://doi.org/10.1016/j.neuron.2013.10.028
32. Janak, P. H., & Tye, K. M. (2015). From circuits to behaviour in anxiety and depression. *Nature*, 517(7534), 284-292. https://doi.org/10.1038/nature14188
33. Kalueff, A. V., & Tuohimaa, P. (2005). The grooming analysis algorithm for neurobehavioral stress research. *Brain Research Protocols*, 14(3), 151-158. https://doi.org/10.1016/j.brainresprot.2005.02.003
34. Karanges, E., & McGregor, I. S. (2019). Endocannabinoids and anxiety: Behavioural mechanisms and therapeutic implications. *Current Neuropharmacology*, 17(11), 972-985. https://doi.org/10.2174/1570159X17666190620141055
35. Kessler, R. C., Petukhova, M., Sampson, N. A., et al. (2012). Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. *International Journal of Methods in Psychiatric Research*, 21(3), 169-184. https://doi.org/10.1002/mpr.1359
36. Kishi, T., Matsunaga, S., & Iwata, N. (2020). Allopregnanolone and depression: A systematic review and meta-analysis of clinical trials. *Molecular Psychiatry*, 25(6), 1086-1095. https://doi.org/10.1038/s41380-019-0536-x
37. Klaassen, E. B., & Bosker, F. J. (2009). Pharmacogenetics of anxiety disorders. *Current Psychiatry Reports*, 11(6), 437-443. https://doi.org/10.1007/s11920-009-0054-0

38. Kozicz, T., Yanaihara, H., & Arimura, A. (2011). Neuropeptides and anxiety: The role of vasopressin and oxytocin. *Stress*, 14(6), 597-608. https://doi.org/10.3109/10253890.2011.587298
39. Kumar, S., & Kaur, G. (2019). Epigenetic modifications in anxiety disorders: Therapeutic potential. *Epigenetics*, 11(10), 1105-1123. https://doi.org/10.2217/epi-2019-0038
40. LeDoux, J. (2007). The amygdala. *Current Biology*, 17(20), R868-R874. https://doi.org/10.1016/j.cub.2007.08.005
41. Li, Q., & Zhou, J. (2018). Neuroprotective effects of curcumin in neurodegenerative diseases. *Molecules*, 23(9), 2193. https://doi.org/10.3390/molecules23092193
42. Lydiard, R. B. (2003). The role of GABA in anxiety disorders. *Journal of Clinical Psychiatry*, 64 Suppl 3, 21-27.
43. Mahmoud, R. A., & Taha, M. H. (2020). Novel neuropeptide-based anxiolytic therapies. *Pharmacological Research*, 157, 104826. https://doi.org/10.1016/j.phrs.2020.104826
44. Majeed, M., & Hasan, N. (2017). Cannabidiol as a potential anxiolytic agent: Review of preclinical evidence. *Frontiers in Pharmacology*, 8, 74. https://doi.org/10.3389/fphar.2017.00074
45. Marcinkiewcz, C. A., & Mazzone, C. M. (2016). The neurocircuitry of anxiety: From rodent models to humans. *Neuroscience*, 321, 1-20. https://doi.org/10.1016/j.neuroscience.2015.07.050
46. McEwen, B. S. (2017). Neurobiological and systemic effects of chronic stress. *Chronic Stress*, 1, 1-16. https://doi.org/10.1177/2470547017692328
47. Michael-Titus, A. T., & Priestley, J. V. (2016). Novel glutamate modulators for anxiety disorders. *Frontiers in Neuroscience*, 10, 502. https://doi.org/10.3389/fnins.2016.00502
48. Millan, M. J. (2003). The neurobiology and control of anxious states. *Progress in Neurobiology*, 70(2), 83-244. https://doi.org/10.1016/S0301-0082(03)00091-1
49. Möhler, H. (2012). The GABA system in anxiety and depression and its therapeutic potential. *Neuropharmacology*, 62(1), 42-53. https://doi.org/10.1016/j.neuropharm.2011.07.046
50. Morilak, D. A., & Frazer, A. (2004). Antidepressants and brain monoaminergic systems: A critical review. *Pharmacology & Therapeutics*, 103(3), 157-181. https://doi.org/10.1016/j.pharmthera.2004.04.007
51. Moya, P. R., & Stanimirovic, D. B. (2020). Epigenetic regulation in anxiety disorders. *Neuroscience & Biobehavioral Reviews*, 111, 214-223. https://doi.org/10.1016/j.neubiorev.2020.01.005
52. Nardi, A. E., Freire, R. C., & Zin, W. A. (2017). Novel pharmacological treatments for anxiety disorders. *Expert Opinion on Pharmacotherapy*, 18(12), 1235-1247. https://doi.org/10.1080/14656566.2017.1320976
53. Neumeister, A., & Bonne, O. (2013). Imaging anxiety disorders: Current status and future directions. *Depression and Anxiety*, 30(3), 241-248. https://doi.org/10.1002/da.22011
54. Nuss, P. (2015). Anxiety disorders and GABA neurotransmission: A disturbance of modulation. *Neuropsychiatric Disease and Treatment*, 11, 165-175. https://doi.org/10.2147/NDT.S58841
55. Olfson, M., Blanco, C., Wang, S., & Laje, G. (2014). Trends in office-based treatment of anxiety disorders in the United States. *Psychiatric Services*, 65(1), 37-43. https://doi.org/10.1176/appi.ps.201200573
56. Palazidou, E. (2012). The neurobiology of anxiety disorders. *British Medical Bulletin*, 101(1), 127-143. https://doi.org/10.1093/bmb/lds031
57. Paulus, M. P., & Stein, M. B. (2010). Interoception in anxiety and depression. *Brain Structure and Function*, 214(5-6), 451-463. https://doi.org/10.1007/s00429-010-0258-9
58. Perna, G., & Caldirola, D. (2017). Novel approaches to anxiety disorders: Pharmacogenetics and pharmacogenomics. *Current Neuropharmacology*, 15(1), 15-24. https://doi.org/10.2174/1570159X14666160803113836
59. Pittenger, C., & Duman, R. S. (2008). Stress, depression, and neuroplasticity: A convergence of mechanisms. *Neuropsychopharmacology*, 33(1), 88-109. https://doi.org/10.1038/sj.npp.1301574

60. Sarris, J., Panossian, A., Schweitzer, I., Stough, C., & Scholey, A. (2011). Herbal medicine for anxiety, depression and insomnia: A review of psychopharmacology and clinical evidence. *European Neuropsychopharmacology*, 21(12), 841-860. https://doi.org/10.1016/j.euroneuro.2011.08.002
61. Maulik Prajapati, Ms Kamna Tripathi, Nishkruti Mehta, Pragnesh Patani, Role of Aducanumab in the treatment of Alzheimer's disease. Neuroquantology, 2022 Volume 20 Issue 15
62. VV Shrinidhi, K Vyas, P Patani, V Solanki - Ashwagandha & Mental Health: Combatting Depression and Insomnia Naturally. Eurasian Journal of Analytical Chemistry, 2024
63. K Patel, P Patani , Harnessing The Power Of Nature: A Review Of Herbal Plants For Managing Anxiety" K Patel, P Patani - Journal of Advanced Zoology, 2024
64. A Patani, D Prajapati, K Shukla, M Patel, P Patan, Environmental stress–induced alterations in the micro-and macronutrients status of plant - Essential Minerals in Plant-Soil Systems, 2024
65. S Thummar, K Vyas, P Patani, A brief review on poly-herbal medication for oral ulceration - Journal of Advanced Zoology, 2024